At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis

Journal of Clinical Oncology

Volumn 29, Issue 10, 2011, Pages 1247-1251

  Cohn, David E ^a   Kim, Kenneth H ^a   Resnick, Kimberly E ^a   O'Malley, David M ^a   Straughn Jr , J Michael ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; BEVACIZUMAB; CARBOPLATIN; PACLITAXEL;

ADD ON THERAPY; ADVANCED CANCER; ARTICLE; BRAIN CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INFUSION; FEBRILE NEUTROPENIA; HUMAN; HYPERTENSION; INTESTINE PERFORATION; KIDNEY CANCER; LUNG CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SENSITIVITY ANALYSIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; DRUG COSTS; FEMALE; HUMANS; INTESTINAL PERFORATION; MODELS, ECONOMIC; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 79953893326     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.1075     Document Type: Article

References (15)

1. Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 60:277-300, 2010
2. Armstrong DK, Bundy B, Wenzel L, et al: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34-43, 2006 (Pubitemid 43048949)
3. Burger RA, Brady MF, Bookman MA, et al: Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. J Clin Oncol 28:5s, 2010 (suppl; abstr LBA1)
4. Kim KJ, Li B, Winer J, et al: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844, 1993 (Pubitemid 23132159)
5. Burger RA, Sill MW, Monk BJ, et al: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group study. J Clin Oncol 25:5165-5171, 2007 (Pubitemid 350237599)
6. Hapani S, Chu D, Wu S: Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: A meta-analysis. Lancet Oncol 10:559-568, 2009
7. Shiroiwa T, Fukuda T, Tsutani K: Costeffectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan. Clin Ther 29:2256-2267, 2007 (Pubitemid 350138568)
8. Krol M, Koopman M, Uyl-de Groot C, et al: A systematic review of economic analyses of pharmaceutical therapies for advanced colorectal cancer. Expert Opin Pharmacother 8:1313-1328, 2007 (Pubitemid 47034417)
9. Jansman FG, Postma MJ, Brouwers JR: Cost considerations in the treatment of colorectal cancer. Pharmacoeconomics 25:537-562, 2007 (Pubitemid 47048039)
10. Uyl-de Groot CA, Giaccone G: Health economics: Can we afford an unrestricted use of new biological agents in gastrointestinal oncology? Curr Opin Oncol 17:392-396, 2005
11. Cannistra SA, Matulonis UA, Penson RT, et al: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180-5186, 2007 (Pubitemid 350232248)
12. Neumann PJ, Sandberg EA, Bell CM, et al: Are pharmaceuticals cost-effective? A review of the evidence. Health Aff (Millwood) 19:92-109, 2000
13. Braithwaite RS, Meltzer DO, King JT Jr, et al: What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 46:349-356, 2008
14. National Institute for Health and Clinical Excellence: Bevacizumab in combination with oxaliplatin and either 5-fluorouracil or capecitabine for the treatment of metastatic colorectal cancer. http://www.nice.org.uk/guidance/ index.jsp?action=article&o=46346
15. Perren T, Swart AM, Pfisterer J, et al: ICON7: A phase III randomised Gynaecologic Cancer Intergroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC). Ann Oncol 21:LB4, 2010 (suppl; abstr)